Biopsy Technique for Endoscopic Surveillance of Hereditary Diffuse Gastric Cancer
Primary Purpose
Hereditary Diffuse Gastric Cancer
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Single bite biopsy technique
Double bite biopsy technique
Sponsored by
About this trial
This is an interventional diagnostic trial for Hereditary Diffuse Gastric Cancer
Eligibility Criteria
Inclusion criteria:
- Patients in the Familial Gastric Cancer Registry held in Cambridge fulfilling clinical criteria for HDGC.
- Patients willing to undergo at least one upper GI endoscopy with random biopsies according to Cambridge biopsy protocol.
Exclusion criteria:
- Patients who decline evaluation with endoscopy either as a screening or surveillance tool
- Patients on clopidogrel, and/or warfarin for high risk condition and unable to withhold temporarily the medication.
Sites / Locations
- MRC Cancer Unit
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Single bite
Double bite
Arm Description
The single bite technique involved removing the forceps with its specimen after each individual biopsy.
The double-bite technique involved taking an initial biopsy, repositioning the forceps, and taking another biopsy from the same area with the initial specimen still on the forceps.
Outcomes
Primary Outcome Measures
Identification of signet ring cell carcinoma (SRCC) foci.
Evaluating the diagnostic yield of the double-bite technique, by means of identifying SRCC foci, in comparison to the conventional single -bite arm.
Secondary Outcome Measures
Time to perform biopsy protocol.
Differences between the study arms in terms of time required for biopsy collection
Biopsy size
Differences between the study arms in terms of size of the biopsy specimens
Patients comfort
Differences between the study arms in terms of patient comfort score, during the procedure. Comfort score is reported after the procedure, according to the modified Gloucester scale.
1: No discomfort - resting comfortably throughout; 2: Minimal. One or two episodes of mild discomfort, well tolerated; 3:Mild. More than 2 episodes of discomfort, adequately tolerated; 4: Moderate. Significant discomfort experienced several times during the procedure; 5: Severe. Extreme discomfort, experienced frequently during the procedure
Dose of sedation.
Differences between the study arms in terms of dose required for sedation
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03950908
Brief Title
Biopsy Technique for Endoscopic Surveillance of Hereditary Diffuse Gastric Cancer
Official Title
Single-bite Versus Double-bite Technique for Mapping Biopsies During Endoscopic Surveillance of Hereditary Diffuse Gastric Cancer: a Single Center, Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
May 2019
Overall Recruitment Status
Completed
Study Start Date
October 12, 2017 (Actual)
Primary Completion Date
December 13, 2018 (Actual)
Study Completion Date
December 13, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Cambridge
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Germline mutation in e-cadherin gene (CDH1) is found in approximately 25% to 30% of individuals fulfilling the clinical criteria for hereditary diffuse gastric cancer (HDGC). Prophylactic gastrectomy is the mainstay of the management of cases with pathogenetic CDH1 mutation. However, some individuals refuse gastrectomy and prefer to delay it for medical or psychosocial reasons. For these patients as well as for those in which a pathogenetic mutation is not found, endoscopic surveillance is recommended. The suggested endoscopic protocol involves targeted as well as 30 random biopsies, which is tedious and time-consuming . In order to save time, two specimens can be taken during a single passage of the biopsy forceps ("double-bite" technique). The aim of this study was to determine the adequacy and utility of the "double-bite" technique in patients undergoing surveillance for HDGC as compared to the standard "single-bite technique".
Detailed Description
Previous studies have validated endoscopy, as an efficient tool for initial screening and in selected cases surveillance of families fulfilling the clinical criteria for hereditary diffuse gastric cancer (HDGC). The aim is to detect microscopic foci of in situ or intramucosal signet ring cell carcinoma (SRCC), which are characteristic of early HDGC. Currently, the recommended endoscopic protocol involves targeted biopsies of any suspicious lesion as well as a minimum of 30 mapping random biopsies specimens taken from all anatomic areas of the gastric mucosa, also known as Cambridge endoscopy protocol. However this is a time-consuming and tedious process, which significantly prolongs the duration of the procedure and might reduce patient tolerance. In order to save time two specimens can be taken during a single passage of the forceps ("double-bite" technique).
In order to evaluate the adequacy and utility of the "double-bite" technique, patients undergoing surveillance for HDGC, are randomized to the single-bite vs double-bite arm. Endoscopies are performed according to a standardized protocol. Briefly, a white-light high-resolution endoscope with 85 magnification and a maximal resolution of 7.9 mm (GIF-FQ260Z; Olympus, Tokyo, Japan) is used to examine all anatomic segments of the insufflated stomach. Any abnormalities on white-light endoscopy are recorded and assessed further by narrow-band imaging magnification with or without autofluorescence imaging. Targeted biopsy specimens are taken from identified lesions, and 5 random biopsy specimens are taken in each of the siz gastric anatomical areas (prepylorus, antrum, transitional zone, body, fundus, and cardia). The double-bite technique involves taking an initial biopsy, repositioning the forceps, and taking another biopsy from the same area with the initial specimen still on the forceps. The single bite technique involves removing the forceps with its specimen after each individual biopsy. Time is recorded between the first and last random biopsy. Comfort score is reported after the procedure, according to the modified Gloucester scale. The investigators use Boston Single-Use Radial Jaw™ 4 biopsy forceps with a spike. Biopsy specimens are stained with hematoxylin and eosin and periodic acid-Schiff diastase and are assessed for size and presence of SRCC foci by an upper specialist GI pathologist, who have significant experience in SRCC identification. Any lesions are checked by a second pathologist within the Cambridge Pathology team before reporting. Both pathologists are blinded to study arm.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hereditary Diffuse Gastric Cancer
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
48 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Single bite
Arm Type
Other
Arm Description
The single bite technique involved removing the forceps with its specimen after each individual biopsy.
Arm Title
Double bite
Arm Type
Other
Arm Description
The double-bite technique involved taking an initial biopsy, repositioning the forceps, and taking another biopsy from the same area with the initial specimen still on the forceps.
Intervention Type
Other
Intervention Name(s)
Single bite biopsy technique
Intervention Description
During biopsy collection one specimen will be retrieved during a single passage of the biopsy forceps.
Intervention Type
Other
Intervention Name(s)
Double bite biopsy technique
Intervention Description
During biopsy collection two specimens will be retrieved during a single passage of the biopsy forceps.
Primary Outcome Measure Information:
Title
Identification of signet ring cell carcinoma (SRCC) foci.
Description
Evaluating the diagnostic yield of the double-bite technique, by means of identifying SRCC foci, in comparison to the conventional single -bite arm.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Time to perform biopsy protocol.
Description
Differences between the study arms in terms of time required for biopsy collection
Time Frame
1 year
Title
Biopsy size
Description
Differences between the study arms in terms of size of the biopsy specimens
Time Frame
1 year
Title
Patients comfort
Description
Differences between the study arms in terms of patient comfort score, during the procedure. Comfort score is reported after the procedure, according to the modified Gloucester scale.
1: No discomfort - resting comfortably throughout; 2: Minimal. One or two episodes of mild discomfort, well tolerated; 3:Mild. More than 2 episodes of discomfort, adequately tolerated; 4: Moderate. Significant discomfort experienced several times during the procedure; 5: Severe. Extreme discomfort, experienced frequently during the procedure
Time Frame
1 year
Title
Dose of sedation.
Description
Differences between the study arms in terms of dose required for sedation
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Patients in the Familial Gastric Cancer Registry held in Cambridge fulfilling clinical criteria for HDGC.
Patients willing to undergo at least one upper GI endoscopy with random biopsies according to Cambridge biopsy protocol.
Exclusion criteria:
Patients who decline evaluation with endoscopy either as a screening or surveillance tool
Patients on clopidogrel, and/or warfarin for high risk condition and unable to withhold temporarily the medication.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Massimiliano di Pietro, MD
Organizational Affiliation
MRC Cancer Unit.University of Cambridge.
Official's Role
Principal Investigator
Facility Information:
Facility Name
MRC Cancer Unit
City
Cambridge
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
25979631
Citation
van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KE, Hardwick RH, Ausems MG, Bardram L, Benusiglio PR, Bisseling TM, Blair V, Bleiker E, Boussioutas A, Cats A, Coit D, DeGregorio L, Figueiredo J, Ford JM, Heijkoop E, Hermens R, Humar B, Kaurah P, Keller G, Lai J, Ligtenberg MJ, O'Donovan M, Oliveira C, Pinheiro H, Ragunath K, Rasenberg E, Richardson S, Roviello F, Schackert H, Seruca R, Taylor A, Ter Huurne A, Tischkowitz M, Joe ST, van Dijck B, van Grieken NC, van Hillegersberg R, van Sandick JW, Vehof R, van Krieken JH, Fitzgerald RC. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015 Jun;52(6):361-74. doi: 10.1136/jmedgenet-2015-103094. Epub 2015 May 15.
Results Reference
background
PubMed Identifier
28688938
Citation
Mi EZ, Mi EZ, di Pietro M, O'Donovan M, Hardwick RH, Richardson S, Ziauddeen H, Fletcher PC, Caldas C, Tischkowitz M, Ragunath K, Fitzgerald RC. Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status. Gastrointest Endosc. 2018 Feb;87(2):408-418. doi: 10.1016/j.gie.2017.06.028. Epub 2017 Jul 6.
Results Reference
background
PubMed Identifier
29706558
Citation
Fewings E, Larionov A, Redman J, Goldgraben MA, Scarth J, Richardson S, Brewer C, Davidson R, Ellis I, Evans DG, Halliday D, Izatt L, Marks P, McConnell V, Verbist L, Mayes R, Clark GR, Hadfield J, Chin SF, Teixeira MR, Giger OT, Hardwick R, di Pietro M, O'Donovan M, Pharoah P, Caldas C, Fitzgerald RC, Tischkowitz M. Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. Lancet Gastroenterol Hepatol. 2018 Jul;3(7):489-498. doi: 10.1016/S2468-1253(18)30079-7. Epub 2018 Apr 27.
Results Reference
background
PubMed Identifier
32679601
Citation
Pappas A, Tan WK, Waldock W, Richardson S, Tripathi M, Januszewicz W, Roberts G, O'Donovan M, Fitzgerald RC, di Pietro M. Single-bite versus double-bite technique for mapping biopsies during endoscopic surveillance for hereditary diffuse gastric cancer: a single-center, randomized trial. Endoscopy. 2021 Mar;53(3):246-253. doi: 10.1055/a-1201-3125. Epub 2020 Jul 17.
Results Reference
derived
Learn more about this trial
Biopsy Technique for Endoscopic Surveillance of Hereditary Diffuse Gastric Cancer
We'll reach out to this number within 24 hrs